Name: 글로벌 시장 동향
SKU: PH7392
Availability: InStock

보고서 요약(국문)

개요
전 세계 염증성 근염 치료 시장은 2022년 YY백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
항체라고도 하는 면역글로불린(Ig)은 형질세포에서 생성되는 당단백질입니다. B세포는 세균 단백질과 같은 특정 면역원에 의해 자극을 받아 형질세포로 분화합니다. 형질세포는 단백질을 생성하는 세포로서 세균, 바이러스, 곰팡이, 기생충, 세포 항원, 화학 물질 및 합성 물질에 대한 체액성 면역 반응에 관여합니다. 면역원 또는 항원은 B림프구 세포 표면의 B세포 수용체와 반응합니다. 이 반응으로 신호가 발생하여 전사 인자가 활성화되고, B세포를 자극한 면역원에 대해 매우 특이적인 항체 합성이 촉진됩니다.

또한, 형질세포에서 생성되는 다양한 면역글로불린은 동형(isotype)으로 분류되며, 각 동형은 구조적 다양성으로 인해 기능과 항원 반응이 다릅니다. 태반 포유류에서 확인된 주요 항체는 IgA, IgD, IgE, IgG, IgM의 다섯 가지입니다. 이러한 분류는 항체 중쇄의 불변 영역에 있는 아미노산 서열의 차이에 기반합니다. IgG와 IgA는 중쇄 아미노산 서열의 추가적인 미세한 차이에 따라 하위 분류로 세분화됩니다. 이러한 면역글로불린은 다양한 자가면역 질환 및 기타 만성 질환 치료에 사용됩니다.
시장 동향: 성장 요인
혁신적인 면역글로불린에 대한 수요 증가
혁신적인 면역글로불린에 대한 수요 증가는 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다. 혁신적인 면역글로불린은 주로 다양한 질병 치료를 위해 개발되었으며, 기존 질환의 관리 및 치료와 관련된 미충족 요구를 해결하고 대안 또는 보완적인 치료 옵션을 제공하는 것을 목표로 합니다. FDA 승인과 같은 규제 기관의 승인 또한 증가하고 있어 면역글로불린의 도입이 더욱 확대되고 있습니다.

예를 들어, 2023년 5월 19일, 애브비(AbbVie)는 미국 식품의약국(FDA)이 재발성 또는 불응성(R/R) 미만성 거대 B세포 림프종(DLBCL, NOS) 성인 환자 치료를 위한 최초이자 유일한 T세포 활성화 이중특이항체인 EPKINLY™(epcoritamab-bysp)를 승인했다고 발표했습니다. 이 치료제는 두 가지 이상의 전신 치료 후에도 재발 또는 불응성인 DLBCL, 그리고 고등급 B세포 림프종(HGBL)을 포함합니다. EPKINLY는 젠맙(Genmab)의 독자적인 듀오바디(DuoBody) 기술을 사용하여 개발된 IgG1 이중특이항체입니다.
또한, 면역글로불린은 전통적으로 원발성 면역결핍 질환 및 자가면역 질환과 같은 질환에 사용되어 왔습니다. 그러나 연구자들과 제약 회사들은 면역글로불린을 이용하여 더 광범위한 질환을 치료하고 진단할 수 있는 잠재력을 탐구하는 데 집중하고 있습니다.

예를 들어, 세계적인 과학 서비스 기업인 Thermo Fisher Scientific은 IVDR 인증을 획득한 후 2023년 8월 24일에 EXENT 솔루션을 출시했습니다. EXENT 솔루션은 다발성 골수종을 포함한 단클론성 감마병증 환자의 진단 및 평가를 혁신하도록 설계된 완전 통합 자동화 질량 분석 시스템입니다. 이 분석기는 IgG, IgA 및 IgM을 측정하고 정량화하는 고감도 및 고특이성 면역 분석법인 EXENT 면역글로불린 동위형(GAM) 면역 분석법과 결합됩니다.
또한, 2022년 3월 29일, Sanofi는 IGM Biosciences와 협력하여 종양학 표적 3개와 면역학/염증 표적 3개를 포함한 총 6개의 면역글로불린 M(IgM) 항체 작용제를 개발, 제조 및 상용화하기로 했습니다.

또한, 면역결핍증 및 기타 면역 관련 질환의 유병률 증가, FDA 승인 증가, 임상 시험 증가, 인식 제고 및 신제품 개발의 발전은 예측 기간 동안 시장 성장을 견인할 것으로 예상되는 요인입니다.
제약 요인
수혈 관련 급성 폐 손상(TRALI), 급성 신부전, IgE 또는 IgA에 대한 IgG 항체에 대한 아나필락시스, 부정맥, 무균성 수막염, 관절염, 간염, 흉막 삼출 및 기타 피부 질환과 같은 면역글로불린의 심각하고 드문 부작용은 시장 성장을 저해할 것으로 예상됩니다.
세분화 분석
세계 면역글로불린 시장은 유형, 형태, 적용 분야, 투여 경로, 최종 사용자 및 지역별로 세분화됩니다.
면역글로불린 G(IgG) 부문은 면역글로불린 시장 점유율의 약 52.1%를 차지했습니다.
면역글로불린 G(IgG) 부문은 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 면역글로불린 G는 IgG1, IgG2, IgG3, IgG4의 네 가지 유형으로 세분화됩니다. IgG는 인체에서 가장 흔하고 풍부한 항체 종류로, 전체 면역글로불린의 약 75~80%를 차지합니다. 혈액과 조직에서 발견되며 장기 면역에 매우 중요합니다. IgG는 독소와 바이러스를 중화시켜 세포 감염을 예방합니다.
또한, 정맥 면역글로불린은 수천 명의 기증자 혈장에서 추출한 IgG 항체를 투여하는 치료법입니다. 이러한 정맥 면역글로불린은 면역결핍 질환 환자의 면역 체계를 강화하고 특정 자가면역 질환에서 면역 반응을 조절하는 데 사용됩니다.
예를 들어, 바이오테스트(Biotest AG)는 2023년 9월 21일 정맥 면역글로불린 이무고(Yimmugo, IgG 차세대)를 출시하여 독일과 오스트리아에 이어 영국에서도 선천성 및 후천성 면역결핍 환자 치료와 면역 조절 용도로 승인을 받았습니다.

또한, 2023년 1월 6일, 에자이 주식회사와 바이오젠 주식회사는 알츠하이머병(AD) 치료를 위해 응집된 가용성 및 불용성 아밀로이드 베타(Aβ) 형태를 표적으로 하는 인간화 면역글로불린 감마 1(IgG1) 단클론 항체인 레카네맙-irmb(LEQEMBI) 100mg/mL 정맥주사제가 미국 식품의약국(FDA)의 승인을 받았다고 발표했습니다.
지역 분석
북미는 시장 점유율의 약 41.1%를 차지했습니다.
북미 지역은 주요 업체들의 강력한 입지와 면역글로불린의 사용 증가로 인해 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 북미, 특히 미국은 제약 회사 및 생명 공학 회사와 같은 주요 업체들의 강력한 입지를 자랑합니다. 이러한 주요 업체들은 다양한 질병 치료를 위한 면역글로불린 제품 개발에 적극적으로 연구 활동을 펼치고 있습니다.

예를 들어, 2023년 4월 11일, 다케다는 미국 식품의약국(FDA)이 2~16세 소아의 원발성 면역결핍증(PI) 치료에 HYQVIA의 사용 범위를 확대하기 위한 추가 생물학적 제제 허가 신청을 승인했다고 발표했습니다. HYQVIA는 한 달에 한 번, 또는 3~4주 간격으로 투여할 수 있는 유일한 피하 면역글로불린 주입제이며, 미국에서는 성인 PI 치료제로 처음 승인되었습니다.
또한, 이 지역에서 면역글로불린의 사용이 증가하고 있는 것도 시장 성장을 견인하고 있습니다. 이 지역에서 면역결핍 질환의 유병률이 지속적으로 증가하고 있으며, 이는 이러한 질환의 치료 및 관리에 면역글로불린을 사용하는 사례를 더욱 늘리고 있습니다. 예를 들어, 알레르기 및 임상 면역학 저널(JACI) 2020에 따르면, 미국에서 원발성 면역결핍 질환의 유병률은 2,000명당 1명으로 추정됩니다.

경쟁 환경
면역글로불린 시장의 주요 글로벌 업체로는 Takeda Pharmaceuticals Inc., CSL Limited, Octapharma AG, Kedrion Biopharma Inc., Grifols, S.A., ADMA Biologics, Inc., Pfizer Inc., Kamada Pharmaceuticals, Cygnus Technologies 및 Emergent BioSolutions Canada Inc. 등이 있습니다.
주요 개발 사항
• 2023년 9월 26일, Takeda는 일본 후생노동성이 무감마글로불린혈증 또는 저감마글로불린혈증¹을 가진 2세 이상 환자에게 CUVITRU[면역글로불린 피하주사제(인간), 20% 용액] 사용을 승인했다고 발표했습니다. 이 질환들은 항체 수치가 매우 낮거나 없어 원발성 또는 이차성 면역결핍으로 인해 심각한 재발성 감염 위험이 증가하는 질환입니다.

• 2021년 2월 18일, 애질런트 테크놀로지스(Agilent Technologies Inc.)는 인체 혈청 또는 혈장에서 SARS-CoV-2에 대한 면역글로불린 G(IgG) 항체를 정성적으로 검출하는 애질런트 다코(Agilent Dako) SARS-CoV-2 IgG 효소면역측정법(ELISA) 키트를 출시했습니다. 이 키트는 애질런트가 미국에서 SARS-CoV-2 검사 시장에 진출했음을 알리는 제품으로, FDA의 "공중보건 비상사태 기간 중 코로나바이러스 감염증-2019 검사 정책" 제4조 D항에 따라 FDA에 신고 절차를 완료했습니다.
• 2020년 11월 10일, 임상 진단 분야의 선두 기업인 베크만 쿨터(Beckman Coulter)는 CE 마크를 인정하는 국가에서 액세스(Access) SARS-CoV-2 면역글로불린 M(IgM) 검사 키트를 출시했습니다. 새로운 IgM 항체 검사는 1,400개의 음성 샘플에서 99.9%의 특이도를, 증상 발현 후 18일 이상 경과하고 PCR 검사에서 양성 반응을 보인 경우 100%의 민감도를 나타냈습니다. 베크만쿨터의 항체 검사 및 향후 출시 예정인 기타 SARS-CoV-2 관련 제품들은 수상 경력에 빛나는 베크만쿨터의 면역 분석기, 특히 시간당 200개의 샘플을 처리할 수 있는 고처리량 분석기인 DxI 800을 기반으로 작동합니다.
COVID-19 영향 분석
COVID-19 팬데믹은 전 세계 면역글로불린 시장에 상당한 영향을 미쳤습니다. COVID-19에 감염된 환자는 감염과 싸우기 위해 항체를 생성합니다. 이러한 항체는 면역글로불린으로 알려져 있으며 COVID-19 대응에 중요한 역할을 합니다. 팬데믹으로 인해 면역글로불린 수요가 증가했습니다.

예를 들어, 2021년 5월 21일 국방연구개발기구(DRDO) 산하 연구소인 국방생리·연대과학연구소(DIPAS)는 혈청 감시를 위한 항체 검출 기반 키트인 'DIPCOVAN', 즉 DIPAS-VDx COVID-19 IgG 항체 마이크로웰 ELISA를 개발했습니다. DIPCOVAN 키트는 SARS-CoV-2 바이러스의 스파이크 단백질과 뉴클레오캡시드(S&N) 단백질을 모두 97%의 높은 민감도와 99%의 특이도로 검출할 수 있습니다.
시장 세분화
유형별
• 면역글로불린 G (IgG)
o IgG1
o IgG2
o IgG3
o IgG4
• 면역글로불린 M (IgM)
• 면역글로불린 A (IgA)
o IgA1
o IgA2
• 면역글로불린 D (IgD)
• 면역글로불린 E (IgE)
형태별
• 가용성 면역글로불린
• 막 결합형 면역글로불린
적용 분야별
• 저감마글로불린혈증
• 만성 염증성 탈수초성 다발신경병증
• 면역결핍 질환
• 중증근무력증
• 특발성 혈소판 감소성 자반증
• 염증성 근병증
• 기타
투여 경로별
• 정맥 주사
• 피하 주사
• 기타
최종 사용자별
• 병원
• 전문 병원 클리닉
• 진단 센터
• 연구 및 학술 센터
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
보고서 구매 이유

• 유형, 형태, 적용 분야, 투여 경로, 최종 사용자 및 지역별 글로벌 면역글로불린 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 식별합니다.
• 모든 세그먼트를 포함한 면역글로불린 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석이 포함된 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 Excel 파일을 제공합니다. 글로벌 면역글로불린 시장 보고서는 약 77개의 표, 84개의 그림, 그리고 187페이지 분량으로 구성됩니다.
주요 독자층 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global inflammatory myositis treatment market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.
Immunoglobulins (Ig) which are also known as antibodies are the glycoproteins produced by plasma cells. B cells are instructed by specific immunogens, such as bacterial proteins, to differentiate into plasma cells, which are protein-making cells that participate in humoral immune responses against bacteria, viruses, fungi, parasites, cellular antigens, chemicals, and synthetic substances. The immunogen or antigen reacts with a B-cell receptor on the cell surface of B lymphocytes. A signal is produced that directs the activation of transcription factors to stimulate the synthesis of antibodies, which are highly specific for the immunogen that stimulated the B cell.
Moreover, the various immunoglobulins produced by plasma cells are classified by isotype, each differs in function and antigen responses primarily due to structure variability. The five major antibody classes that have been identified in placental mammals, they are IgA, IgD, IgE, IgG, and IgM. This classification is based on differences in amino acid sequence in the constant region of the antibody heavy chains. IgG and IgA are further grouped into subclasses based on additional small differences in the amino acid heavy chain sequences. These are used to treat many autoimmune and other chronic disorders.
Market Dynamics: Drivers
Increasing demand for innovative immunoglobulins
The increasing demand for innovative immunoglobulins is expected to drive the market over the forecast period. The innovative immunoglobulins are mainly designed to treat various types of diseases and they aim to address the unmet needs associated with the management and treatment of various disorders by providing alternative or complementary treatment options. Regulatory approvals such as FDA approvals are also increasing, which further increases the adoption of immunoglobulins.
For instance, on May 19, 2023, AbbVie, cleared that the U.S. Food and Drug Administration (FDA) has approved EPKINLYTM (epcoritamab-bysp), as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), including DLBCL arising from indolent lymphoma, and high-grade B–cell lymphoma (HGBL), after two or more lines of systemic therapies. EPKINLY is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody technology.
Moreover, immunoglobulins have traditionally been used for conditions such as primary immunodeficiency disorders and autoimmune diseases. However, researchers and pharmaceutical companies are focussing on exploring their potential for treating and diagnosing a broader range of conditions by using immunoglobulins.
For instance, on August 24, 2023, Thermo Fisher Scientific, the world leader in serving science, launched the EXENT Solution, after receiving IVDR certification. The EXENT solution is a fully integrated and automated mass spectrometry system designed to transform diagnosis and assessment for patients with monoclonal gammopathies, including multiple myeloma. The analyzer is combined with the EXENT Immunoglobulin Isotypes (GAM) immunoassay, a highly sensitive and specific immunoassay for measuring and quantifying IgG, IgA, and IgM.
Additionally, on March 29, 2022, Sanofi partnered with IGM Biosciences to create, develop, manufacture and commercialize six immunoglobulin M (IgM) antibody agonists, three against oncology targets and the other three against immunology/inflammation targets.
Further, the increasing prevalence of immunodeficiency and other immune-related disorders, rising FDA approvals, increasing clinical trials, increasing awareness and advancements in the development of novel products are the factors expected to drive the market over the forecast period.
Restraints
Factors such as severe and rare side effects of immunoglobulins like transfusion-related acute lung injury (TRALI), acute renal failure, anaphylaxis to IgE or IgG antibodies to IgA, arrhythmias, aseptic meningitis, arthritis, hepatitis, pleural effusion and other dermatological manifestations are expected to hamper the market.
Segment Analysis
The global immunoglobulin market is segmented based on type, form, application, route of administration, end-user and region.
The immunoglobulin G (IgG) segment accounted for approximately 52.1% of the immunoglobulin market share
The immunoglobulin G (IgG) segment is expected to hold the largest market share over the forecast period. Immunoglobulin G is further subdivided into four types, they are IgG1, IgG2, IgG3 and IgG4. IgG is the most commonly abundant class of antibodies in the human body, constituting about 75-80% of the total immunoglobulin pool. It is found in the blood and tissues and is crucial for long-term immunity. IgG can neutralize toxins and viruses, preventing them from infecting cells.
Furthermore, intravenous immunoglobulins involve the administration of IgG antibodies extracted from the plasma of thousands of donors. These intravenous immunoglobulins are used to boost the immune system in patients with immunodeficiency disorders and to modulate immune responses in certain autoimmune conditions.
For instance, on September 21, 2023, Biotest AG launched its intravenous immunoglobulin Yimmugo (IgG Next Generation) and got approval in the United Kingdom for the treatment of patients with congenital and acquired immunodeficiencies and for immunomodulation, following approvals in Germany and Austria.
Additionally, on January 6, 2023, Eisai Co., Ltd. and Biogen Inc. released the approval from U.S. Food and Drug Administration (FDA) for lecanemab-irmb (LEQEMBI) 100 mg/mL injection for intravenous use, a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta (Aβ) for the treatment of Alzheimer's disease (AD).
Geographical Analysis
North America accounted for approximately 41.1% of the market share
North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing adoption of immunoglobulins. North America especially the United States is known for its strong presence of major players such as pharmaceutical companies and biotechnology companies. The presence of major players actively performing research activities to develop immunoglobulin products for the treatment of various diseases.
For instance, on April 11, 2023, Takeda cleared that the U.S. Food and Drug Administration (FDA) has approved a supplemental biologics license application to expand the use of HYQVIA to treat primary immunodeficiency (PI) in children 2-16 years old. HYQVIA is the only subcutaneous immune globulin infusion that can be administered once a month, every three or four weeks and was first approved in the U.S. for the treatment of PI in adults.
Furthermore, the increasing adoption of immunoglobulins in the region is also driving the market in the region. There is a continuously increasing prevalence of immunodeficiency disorders in the region, further increasing the adoption of immunoglobulins for the treatment and management of these disorders. For instance, according to the Journal of Allergy and Clinical Immunology (JACI), 2020, the prevalence of primary immunodeficiency disorders in the United States is estimated at 1 in 2000 individuals.
Competitive Landscape
The major global players in the immunoglobulin market include Takeda Pharmaceuticals Inc., CSL Limited, Octapharma AG, Kedrion Biopharma Inc., Grifols, S.A., ADMA Biologics, Inc., Pfizer Inc., Kamada Pharmaceuticals, Cygnus Technologies and Emergent BioSolutions Canada Inc. among others.
Key Developments
• On September 26, 2023, Takeda released that the Japanese Ministry of Health, Labour and Welfare has approved the use of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] in patients aged 2 years and older with agammaglobulinemia or hypogammaglobulinemia1, disorders characterized by very low or absent levels of antibodies and an increased risk of serious recurring infection caused by primary immunodeficiency or secondary immunodeficiency.
• On February 18, 2021, Agilent Technologies Inc. launched the Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit intended for the qualitative detection of immunoglobulin G (IgG) antibodies to SARS-CoV-2 in human serum or plasma. The kit, which marks Agilent’s entrance into SARS-CoV-2 testing in the US, has completed the notification process to the FDA in accordance with Section IV.D of FDA’s “Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency”.
• On November 10, 2020, Beckman Coulter, a clinical diagnostics leader, launched its Access SARS-CoV-2 Immunoglobulin M (IgM) assay in countries accepting the CE Mark. The new IgM antibody test demonstrated 99.9% specificity with 1,400 negative samples and 100% sensitivity at >18 days post-symptom onset and positive PCR. Beckman Coulter’s antibody assays and its other planned SARS-CoV-2 offerings run on the organization’s award-winning immunoassay analyzers, including the DxI 800 high-throughput analyzer, which is capable of processing 200 samples per hour.
COVID-19 Impact Analysis
The COVID-19 pandemic significantly impacted the global immunoglobulin market. When infected with COVID-19, patients produce antibodies to fight off the infection. These antibodies are known as immunoglobulins and are key players in the response to COVID-19. The demand for immunoglobulins has increased due to the pandemic.
For instance, on May 21, 2021, the Defence Institute of Physiology and Allied Sciences (DIPAS), a laboratory of the Defence Research and Development Organisation (DRDO), developed an antibody detection-based kit 'DIPCOVAN', the DIPAS-VDx COVID-19 IgG Antibody Microwell ELISA for sero-surveillance. The DIPCOVAN kit can detect both spikes as well as nucleocapsid (S&N) proteins of SARS-CoV-2 virus with a high sensitivity of 97 percent and specificity of 99 percent.
Market Segmentation
By Type
• Immunoglobulin G (IgG)
o IgG1
o IgG2
o IgG3
o IgG4
• Immunoglobulin M (IgM)
• Immunoglobulin A (IgA)
o IgA1
o IgA2
• Immunoglobulin D (IgD)
• Immunoglobulin E (IgE)
By Form
• Soluble Immunoglobulins
• Membrane-Bound Immunoglobulins
By Application
• Hypogammaglobulinemia
• Chronic Inflammatory Demyelinating Polyneuropathy
• Immunodeficiency Disorders
• Myasthenia Gravis
• Idiopathic Thrombocytopenic Purpura
• Inflammatory Myopathies
• Others
By Route of Administration
• Intravenous
• Subcutaneous
• Others
By End-User
• Hospitals
• Specialty Clinics
• Diagnostic Centers
• Research and Academic Centers
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Why Purchase the Report?
• To visualize the global immunoglobulin market segmentation based on type, form, application, route of administration, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of immunoglobulin market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global immunoglobulin market report would provide approximately 77 tables, 84 figures, and 187 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Form
3.3. Snippet by Application
3.4. Snippet by Route of Administration
3.5. Snippet by End-User
3.6. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Demand for Innovative Immunoglobulins
4.1.2. Restraints
4.1.2.1. Severe Side Effects of Immunoglobulins
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Unmet Needs
5.7. Patent Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Immunoglobulin G (IgG)*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. IgG1
7.2.4. IgG2
7.2.5. IgG3
7.2.6. IgG4
7.3. Immunoglobulin M (IgM)
7.4. Immunoglobulin A (IgA)
7.4.1. IgA1
7.4.2. IgA2
7.5. Immunoglobulin D (IgD)
7.6. Immunoglobulin E (IgE)
8. By Form
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
8.1.2. Market Attractiveness Index, By Form
8.2. Soluble Immunoglobulins*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Membrane-Bound Immunoglobulins
9. By Application
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.1.2. Market Attractiveness Index, By Application
9.2. Hypogammaglobulinemia*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Chronic Inflammatory Demyelinating Polyneuropathy
9.4. Immunodeficiency Disorders
9.5. Myasthenia Gravis
9.6. Idiopathic Thrombocytopenic Purpura
9.7. Inflammatory Myopathies
9.8. Others
10. By Route of Administration
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.1.2. Market Attractiveness Index, By Route of Administration
10.2. Intravenous*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Subcutaneous
10.4. Others
11. By End-User
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.1.2. Market Attractiveness Index, By End-User
11.2. Hospitals*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Specialty Clinics
11.4. Diagnostic Centers
11.5. Research and Academic Centers
11.6. Others
12. By Region
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.8.1. U.S.
12.2.8.2. Canada
12.2.8.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.8.1. Germany
12.3.8.2. UK
12.3.8.3. France
12.3.8.4. Italy
12.3.8.5. Spain
12.3.8.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.8.1. Brazil
12.4.8.2. Argentina
12.4.8.3. Rest of South America
12.5. Asia-Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.8.1. China
12.5.8.2. India
12.5.8.3. Japan
12.5.8.4. Australia
12.5.8.5. Rest of Asia-Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
13. Competitive Landscape
13.1. Competitive Scenario
13.2. Market Positioning/Share Analysis
13.3. Mergers and Acquisitions Analysis
14. Company Profiles
14.1. Takeda Pharmaceuticals Inc.*
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. CSL Limited
14.3. Octapharma AG
14.4. Kedrion Biopharma Inc.
14.5. Grifols, S.A.
14.6. ADMA Biologics, Inc.
14.7. Pfizer Inc.
14.8. Kamada Pharmaceuticals
14.9. Cygnus Technologies
14.10. Emergent BioSolutions Canada Inc.
LIST NOT EXHAUSTIVE
15. Appendix
15.1. About Us and Services
15.2. Contact Us

언급된 주요 기업들

Takeda Pharmaceuticals Inc., 4.	Key Developments, CSL Limited, Octapharma AG, Kedrion Biopharma Inc., Grifols, S.A., ADMA Biologics, Inc., Pfizer Inc., Kamada Pharmaceuticals, Cygnus Technologies, Emergent BioSolutions Canada Inc.

표 목록 (Tables)

List of Tables Table 1 Global Immunoglobulin Market Value, By Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Immunoglobulin Market Value, By Form, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Immunoglobulin Market Value, By Application, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Immunoglobulin Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Immunoglobulin Market Value, By End-User, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Immunoglobulin Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 7 Global Immunoglobulin Market Value, By Type, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Immunoglobulin Market Value, By Type, 2021-2030 (US$ Million)

Table 9 Global Immunoglobulin Market Value, By Form, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Immunoglobulin Market Value, By Form, 2021-2030 (US$ Million)

Table 11 Global Immunoglobulin Market Value, By Application, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Immunoglobulin Market Value, By Application, 2021-2030 (US$ Million)

Table 13 Global Immunoglobulin Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 14 Global Immunoglobulin Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 15 Global Immunoglobulin Market Value, By End-User, 2022, 2026 & 2030 (US$ Million)

Table 16 Global Immunoglobulin Market Value, By End-User, 2021-2030 (US$ Million)

Table 17 Global Immunoglobulin Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 18 Global Immunoglobulin Market Value, By Region, 2021-2030 (US$ Million)

Table 19 North America Immunoglobulin Market Value, By Type, 2021-2030 (US$ Million)

Table 20 North America Immunoglobulin Market Value, By Form, 2021-2030 (US$ Million)

Table 21 North America Immunoglobulin Market Value, By Application, 2021-2030 (US$ Million)

Table 22 North America Immunoglobulin Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 23 North America Immunoglobulin Market Value, By End-User, 2021-2030 (US$ Million)

Table 24 North America Immunoglobulin Market Value, By Country, 2021-2030 (US$ Million)

Table 25 South America Immunoglobulin Market Value, By Type, 2021-2030 (US$ Million)

Table 26 South America Immunoglobulin Market Value, By Form, 2021-2030 (US$ Million)

Table 27 South America Immunoglobulin Market Value, By Application, 2021-2030 (US$ Million)

Table 28 South America Immunoglobulin Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 29 South America Immunoglobulin Market Value, By End-User, 2021-2030 (US$ Million)

Table 30 South America Immunoglobulin Market Value, By Country, 2021-2030 (US$ Million)

Table 31 Europe Immunoglobulin Market Value, By Type, 2021-2030 (US$ Million)

Table 32 Europe Immunoglobulin Market Value, By Form, 2021-2030 (US$ Million)

Table 33 Europe Immunoglobulin Market Value, By Application, 2021-2030 (US$ Million)

Table 34 Europe Immunoglobulin Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 35 Europe Immunoglobulin Market Value, By End-User, 2021-2030 (US$ Million)

Table 36 Europe Immunoglobulin Market Value, By Country, 2021-2030 (US$ Million)

Table 37 Asia-Pacific Immunoglobulin Market Value, By Type, 2021-2030 (US$ Million)

Table 38 Asia-Pacific Immunoglobulin Market Value, By Form, 2021-2030 (US$ Million)

Table 39 Asia-Pacific Immunoglobulin Market Value, By Application, 2021-2030 (US$ Million)

Table 40 Asia-Pacific Immunoglobulin Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 41 Asia-Pacific Immunoglobulin Market Value, By End-User, 2021-2030 (US$ Million)

Table 42 Asia-Pacific Immunoglobulin Market Value, By Country, 2021-2030 (US$ Million)

Table 43 Middle East & Africa Immunoglobulin Market Value, By Type, 2021-2030 (US$ Million)

Table 44 Middle East & Africa Immunoglobulin Market Value, By Form, 2021-2030 (US$ Million)

Table 45 Middle East & Africa Immunoglobulin Market Value, By Application, 2021-2030 (US$ Million)

Table 46 Middle East & Africa Immunoglobulin Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 47 Middle East & Africa Immunoglobulin Market Value, By End-User, 2021-2030 (US$ Million)

Table 48 Takeda Pharmaceuticals Inc.: Overview

Table 49 Takeda Pharmaceuticals Inc.: Product Portfolio

Table 50 Takeda Pharmaceuticals Inc.: Key Developments

Table 51 CSL Limited: Overview

Table 52 CSL Limited: Product Portfolio

Table 53 CSL Limited: Key Developments

Table 54 Octapharma AG: Overview

Table 55 Octapharma AG: Product Portfolio

Table 56 Octapharma AG: Key Developments

Table 57 Kedrion Biopharma Inc.: Overview

Table 58 Kedrion Biopharma Inc.: Product Portfolio

Table 59 Kedrion Biopharma Inc.: Key Developments

Table 60 Grifols, S.A.: Overview

Table 61 Grifols, S.A.: Product Portfolio

Table 62 Grifols, S.A.: Key Developments

Table 63 ADMA Biologics, Inc.: Overview

Table 64 ADMA Biologics, Inc.: Product Portfolio

Table 65 ADMA Biologics, Inc.: Key Developments

Table 66 Pfizer Inc.: Overview

Table 67 Pfizer Inc.: Product Portfolio

Table 68 Pfizer Inc.: Key Developments

Table 69 Kamada Pharmaceuticals: Overview

Table 70 Kamada Pharmaceuticals: Product Portfolio

Table 71 Kamada Pharmaceuticals: Key Developments

Table 72 Cygnus Technologies: Overview

Table 73 Cygnus Technologies: Product Portfolio

Table 74 Cygnus Technologies: Key Developments

Table 75 Emergent BioSolutions Canada Inc.: Overview

Table 76 Emergent BioSolutions Canada Inc.: Product Portfolio

Table 77 Emergent BioSolutions Canada Inc.: Key Developments

그림 목록 (Figures)

List of Figures Figure 1 Global Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 2 Global Immunoglobulin Market Share, By Type, 2022 & 2030 (%)

Figure 3 Global Immunoglobulin Market Share, By Form, 2022 & 2030 (%)

Figure 4 Global Immunoglobulin Market Share, By Application, 2022 & 2030 (%)

Figure 5 Global Immunoglobulin Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 6 Global Immunoglobulin Market Share, By End-User, 2022 & 2030 (%)

Figure 7 Global Immunoglobulin Market Share, By Region, 2022 & 2030 (%)

Figure 8 Global Immunoglobulin Market Y-o-Y Growth, By Type, 2022-2030 (%)

Figure 9 Immunoglobulin G (IgG) Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 10 Immunoglobulin M (IgM) Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 11 Immunoglobulin A (IgA) Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 12 Immunoglobulin D (IgD) Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 13 Immunoglobulin E (IgE) Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 14 Global Immunoglobulin Market Y-o-Y Growth, By Form, 2022-2030 (%)

Figure 15 Soluble Immunoglobulins Form in Global Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 16 Membrane-Bound Immunoglobulins Form in Global Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 17 Global Immunoglobulin Market Y-o-Y Growth, By Application, 2022-2030 (%)

Figure 18 Hypogammaglobulinemia Application in Global Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 19 Chronic Inflammatory Demyelinating Polyneuropathy Application in Global Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 20 Immunodeficiency Disorders Application in Global Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 21 Myasthenia Gravis Application in Global Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 22 Idiopathic Thrombocytopenic Purpura Application in Global Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 23 Inflammatory Myopathies Application in Global Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 24 Others Application in Global Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 25 Global Immunoglobulin Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 26 Intravenous Route of Administration in Global Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 27 Subcutaneous Route of Administration in Global Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 28 Others Route of Administration in Global Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 29 Global Immunoglobulin Market Y-o-Y Growth, By End-User, 2022-2030 (%)

Figure 30 Hospitals End-User in Global Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 31 Specialty Clinics End-User in Global Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 32 Diagnostic Centers End-User in Global Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 33 Research and Academic Centers End-User in Global Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 34 Others End-User in Global Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 35 Global Immunoglobulin Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 36 North America Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 37 Asia-Pacific Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 38 Europe Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 39 South America Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 40 Middle East and Africa Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 41 North America Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 42 North America Immunoglobulin Market Share, By Type, 2022 & 2030 (%)

Figure 43 North America Immunoglobulin Market Share, By Form, 2022 & 2030 (%)

Figure 44 North America Immunoglobulin Market Share, By Application, 2022 & 2030 (%)

Figure 45 North America Immunoglobulin Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 46 North America Immunoglobulin Market Share, By End-User, 2022 & 2030 (%)

Figure 47 North America Immunoglobulin Market Share, By Country, 2022 & 2030 (%)

Figure 48 South America Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 49 South America Immunoglobulin Market Share, By Type, 2022 & 2030 (%)

Figure 50 South America Immunoglobulin Market Share, By Form, 2022 & 2030 (%)

Figure 51 South America Immunoglobulin Market Share, By Application, 2022 & 2030 (%)

Figure 52 South America Immunoglobulin Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 53 South America Immunoglobulin Market Share, By End-User, 2022 & 2030 (%)

Figure 54 South America Immunoglobulin Market Share, By Country, 2022 & 2030 (%)

Figure 55 Europe Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 56 Europe Immunoglobulin Market Share, By Type, 2022 & 2030 (%)

Figure 57 Europe Immunoglobulin Market Share, By Form, 2022 & 2030 (%)

Figure 58 Europe Immunoglobulin Market Share, By Application, 2022 & 2030 (%)

Figure 59 Europe Immunoglobulin Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 60 Europe Immunoglobulin Market Share, By End-User, 2022 & 2030 (%)

Figure 61 Europe Immunoglobulin Market Share, By Country, 2022 & 2030 (%)

Figure 62 Asia-Pacific Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 63 Asia-Pacific Immunoglobulin Market Share, By Type, 2022 & 2030 (%)

Figure 64 Asia-Pacific Immunoglobulin Market Share, By Form, 2022 & 2030 (%)

Figure 65 Asia-Pacific Immunoglobulin Market Share, By Application, 2022 & 2030 (%)

Figure 66 Asia-Pacific Immunoglobulin Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 67 Asia-Pacific Immunoglobulin Market Share, By End-User, 2022 & 2030 (%)

Figure 68 Asia-Pacific Immunoglobulin Market Share, By Country, 2022 & 2030 (%)

Figure 69 Middle East & Africa Immunoglobulin Market Value, 2021-2030 (US$ Million)

Figure 70 Middle East & Africa Immunoglobulin Market Share, By Type, 2022 & 2030 (%)

Figure 71 Middle East & Africa Immunoglobulin Market Share, By Form, 2022 & 2030 (%)

Figure 72 Middle East & Africa Immunoglobulin Market Share, By Application, 2022 & 2030 (%)

Figure 73 Middle East & Africa Immunoglobulin Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 74 Middle East & Africa Immunoglobulin Market Share, By End-User, 2022 & 2030 (%)

Figure 75 Takeda Pharmaceuticals Inc.: Financials

Figure 76 CSL Limited: Financials

Figure 77 Octapharma AG: Financials

Figure 78 Kedrion Biopharma Inc.: Financials

Figure 79 Grifols, S.A.: Financials

Figure 80 ADMA Biologics, Inc.: Financials

Figure 81 Pfizer Inc.: Financials

Figure 82 Kamada Pharmaceuticals: Financials

Figure 83 Cygnus Technologies: Financials

Figure 84 Emergent BioSolutions Canada Inc.: Financials

글로벌 면역글로불린 시장 – 2023-2030

Global Immunoglobulin Market - 2023-2030